Longitudinal virological changes and underlying pathogenesis in hospitalized COVID-19 patients in Guangzhou,China

Science China Life Sciences - Prolonged viral RNA shedding and recurrence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in coronavirus disease 2019 (COVID-19) patients have been...     

外泌体提取及保存技术研究进展

外泌体是多种活细胞经过"内吞–融合–外排"等一系列过程主动向胞外分泌的纳米级双层膜结构小囊泡,广泛存在于血液和尿液等生物体液中。因其携带着多种蛋白质、核酸和脂质等生物活性分子,所以外泌体不仅在细胞间物质交换和信息传递中发挥重要作用,而且对疾病诊断、预后预测和治疗管理等均具有提示意义。外泌体的高效提取、分离和完整保存是研究其在机体内生物学作用和功能的重要前提,也是制约基于外泌体的临床检测技术和治疗载体技术的关键。该综述将针对目前国内外外泌体提取和保存领域的最新研究进展加以综述,并对其特点进行对比和分析,以促进外泌体研究方法的标准化,以及相关技术的研发和应用拓展。     

Transmission of synovial sarcoma from a single multi-organ donor to three transplant recipients: case report

Quick and reliable testing of EGFR and KRAS is needed in non-small cell lung cancer (NSCLC) to ensure optimal decision-making for targeted therapy. The Idylla™ platform was designed for Formalin-Fixed Paraffin-Embedded (FFPE) tissue sections but recently several studies were published that evaluated its potential for cytological specimens. This study aimed to validate the Idylla™ platform for the detection of EGFR/KRAS mutations in cytological NSCLC samples prepared as cytoblocks using AGAR and paraffin embedding. The KRAS Idylla™ test were performed on 11 specimens with a known KRAS mutation. The EGFR Idylla™ test was performed on 18 specimens with a known primary EGFR mutation and 7 specimens with a primary EGFR-EGFR T790M resistance mutation combination. Concordant KRAS and primary EGFR mutations were detected for both KRAS and primary EGFR mutations. Samples with a total CQ value of < 26 could be considered negative. Samples with a total CQ value of > 26 could not be assessed (probability of false-negative). In specimens with a primary EGFR-EGFR T790M resistance mutation combination, 5/7 cases were not concordant. Our results confirm the conclusion of recent reports that the Idylla™EGFR assay is not suitable in a resistance to EGFR TKI setting, also not in our cytological NSCLC samples prepared as cytoblocks using AGAR and paraffin embedding. KRAS and primary EGFR mutations were detected using the Idylla™ assays in virtually all cytological NSCLC samples. This analysis was rapid and time-saving compared to other mutation detection assays and may be useful if the amount of material is insufficient to perform a full set of molecular tests.     

LBX2-AS1 promotes ovarian cancer progression by facilitating E2F2 gene expression via miR-455-5p and miR-491-5p sponging

LBX2-AS1 is a long non-coding RNA that facilitates the development of gastrointestinal cancers and lung cancer, but its participation in ovarian cancer development remained uninvestigated. Clinical data retrieved from TCGA ovarian cancer database and the clinography of 60 ovarian cancer patients who received anti-cancer treatment in our facility were analysed. The overall cell growth, colony formation, migration, invasion, apoptosis and tumour formation on nude mice of ovarian cancer cells were evaluated before and after lentiviral-based LBX2-AS1 knockdown. ENCORI platform was used to explore LBX2-AS1-interacting microRNAs and target genes of the candidate microRNAs. Luciferase reporter gene assay and RNA pulldown assay were used to verify the putative miRNA-RNA interactions. Ovarian cancer tissue specimens showed significant higher LBX2-AS1 expression levels that non-cancerous counterparts. High expression level of LBX2-AS1 was significantly associated with reduced overall survival of patients. LBX2-AS1 knockdown significantly down-regulated the cell growth, colony formation, migration, invasion and tumour formation capacity of ovarian cancer cells and increased their apoptosis in vitro. LBX2-AS1 interacts with and thus inhibits the function of miR-455-5p and miR-491-5p, both of which restrained the expression of E2F2 gene in ovarian cancer cells via mRNA targeting. Transfection of miRNA inhibitors of these two miRNAs or forced expression of E2F2 counteracted the effect of LBX2-AS1 knockdown on ovarian cancer cells. LBX2-AS1 was a novel cancer-promoting lncRNA in ovarian cancer. This lncRNA increased the cell growth, survival, migration, invasion and tumour formation of ovarian cancer cells by inhibiting miR-455-5p and miR-491-5p, thus liberating the expression of E2F2 cancer-promoting gene.     

ARL4C might serve as a prognostic factor and a novel therapeutic target for gastric cancer: bioinformatics analyses and biological experiments

The ADP-ribosylation factor-like proteins (ARLs) have been proved to regulate the malignant phenotypes of several cancers. However, the exact role of ARLs in gastric cancer (GC) remains elusive. In this study, we systematically investigate the expression status, interactive relations, potential pathways, genetic variations and clinical values of ARLs in GC. We find that ARLs are significantly dysregulated in GC and involved in various cancer-related pathways. Subsequently, machine learning models identify ARL4C as one of the two most significant clinical indicators among ARLs for GC. Furthermore, ARL4C silencing remarkably inhibits the growth and metastasis of GC cells both in vitro and in vivo. Moreover, enrichment analysis indicates that ARL4C is highly correlated with TGF-β1 signalling. Correspondingly, TGF-β1 treatment dramatically increases ARL4C expression and ARL4C knockdown inhibits the phosphorylation level of Smads, downstream factors of TGF-β1. Meanwhile, the coexpression of ARL4C and TGF-β1 worsens the prognosis of GC patients. Our work comprehensively demonstrates the crucial role of ARLs in the carcinogenesis of GC and the specific mechanisms underlying the GC-promoting effects of TGF-β1. More importantly, we uncover the great promise of ARL4C-targeted therapy in improving the efficacy of TGF-β1 inhibitors for GC patients.     

Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis

Apoptosis - Resistance to epidermal growth factor receptor-tyrosin kinase inhibitors (TKIs, e.g. icotinib) remains a major clinical challenge. Non-small cell lung cancer patients with wild-type...     

传染性单核细胞增多症患者外周血T细胞亚群检测及临床意义

目的检测传染性单核细胞增多症(IM)患者及非本病的发热患者外周血T淋巴细胞亚群,探讨EB病毒感染导致的传染性单核细胞增多症的免疫反应机制及与非本病发热患者的鉴别诊断价值,同时通过检测患者血液中的EBV-DNA载量加以确证。方法选取确诊为传染性单核细胞增多症的患者30例(IM组),非传染性单核细胞增多症的发热患者30例(对照组)。应用流式细胞技术检测患者外周血中淋巴细胞亚群,同时应用荧光定量PCR技术检测血清EBV-DNA载量,采用卡方检验及Mann-Whitney检验进行组间差异分析。结果 IM组与对照组患者T淋巴细胞亚群相比,CD8~+T淋巴细胞所占比例显著升高(Z=1.776,P0.001),CD4~+T淋巴细胞所占比例降低(F=4.008,P0.050),同时CD4~+/CD8~+比例明显下降(Z=6.653,P0.001)。IM组EBV-DNA病毒载量显著高于对照组,差异具有统计学意义(P0.050)。结论传染性单核细胞增多症患者外周血T淋巴细胞亚群主要以CD4~+T淋巴细胞及CD8~+T淋巴细胞的变化为主,T淋巴细胞亚群结合血清EBV-DNA病毒载量的联合检测对IM及非本病的发热患者具有鉴别诊断价值。     

大连地区分泌型与非分泌型母亲母乳菌群结构的差异

目的探讨大连地区分泌型和非分泌型母亲哺乳期间母乳菌群的主要差异。方法于大连市妇幼保健院纳入42名志愿者产妇,收集其产后第6天的母乳样本。提取母乳样本DNA,并对包含rs601338和rs1047781单核酸位点多态性(SNP)的片段用聚合酶链式反应(polymerase chain reaction,PCR)检测并加以测序,以检测受试母亲岩藻糖基转移酶2基因(FUT2)的类型。采用16S rRNA高通量测序法对不同母乳样本中微生物的多样性进行分析,并且对不同母乳样本中的微生物丰度及类型展开探讨。结果母亲分泌型分布情况分析:42名志愿者中,36名母亲是分泌型,6名母亲是非分泌型。母乳菌群多样性分析:分泌型与非分泌型组母亲母乳菌群比较,发现反映组内差异的Alpha多样性指数(包括Ace、Chao1以及Shannon等)在2组间差异无统计学意义;通过使用主坐标分析,发现分泌型组和非分泌型组的距离相对较远,母乳菌群组内菌群结构类似,组间差异性较显著,说明母乳中的蛋白核心岩藻糖基化水平可明显改变母乳中菌群结构。乳汁菌群物种构成分析:从门水平分析,变形菌门与厚壁菌门为主要优势菌;从属水平分析,2组母乳菌群中的双歧杆菌属丰度差异较显著。相关性分析:分泌型母乳的菌群中相关基因的表达更强,说明分泌型母乳对菌群基因的表达有促进作用。结论母乳菌群构成在一定程度上受到母体FUT2基因类型,即母亲分泌型和非分泌型的影响。